HKPD revenueFY2026$13.43M
- FY YoY
- -33.9%
HKPD revenue was $13.43M for fiscal 2026 (ended Mar 31, 2026), down 33.9% from fiscal 2025. It rose in 2 of the last 3 fiscal years.
Cellyan Biotechnology Co. Ltd (HKPD) financials
For fiscal 2026 (ended Mar 31, 2026), Cellyan Biotechnology Co. Ltd reported $13.43M of revenue and -$1.14M of net income.
- Revenue, FY2026
- $13.43M
- Revenue growth, YoY
- -33.9%
- Net income, FY2026
- -$1.14M
- Net margin
- -8.5%
- Free cash flow, FY2026
- -$787.1K
- EPS, diluted, FY2026
- -$0.07
- Cash
- $221.8K
- Total debt
- $877.9K
- P/S
- 0.28
- Market cap
- $3.8M
FY2023FY2026
FY2023FY2026
FY2023FY2026
HKPD revenue and earnings growth
HKPD net incomeFY2026-$1.14M
HKPD net income was -$1.14M for fiscal 2026 (ended Mar 31, 2026), compared with -$27.1K in fiscal 2025.
HKPD EPSFY2026-$0.07
HKPD diluted EPS was -$0.07 for fiscal 2026 (ended Mar 31, 2026).
HKPD free cash flowFY2026-$787.1K
HKPD free cash flow was -$787.1K for fiscal 2026 (ended Mar 31, 2026), compared with $499.3K in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Revenue | $13.43M | $20.31M | $16.69M | $12.56M |
| Cost of revenue | $12.05M | $17.90M | $13.13M | $9.82M |
| Gross profit | $1.39M | $2.42M | $3.56M | $2.74M |
| Selling, general and admin | $2.40M | $2.22M | $1.89M | $1.76M |
| Operating income | -$2.39M | -$2.28M | -$1.95M | -$1.79M |
| Interest expense | $133.8K | $97.7K | $82.8K | $23.2K |
| Pre-tax income | -$1.13M | $36.1K | $1.53M | $1.02M |
| Income tax | $7.7K | $63.2K | $196.3K | $22.6K |
| Net income | -$1.14M | -$27.1K | $1.33M | $998.2K |
| EPS, basic | -$0.07 | -$0.00 | $0.18 | $0.15 |
| EPS, diluted | -$0.07 | -$0.00 | $0.18 | $0.15 |
| Diluted shares | 16.3M | 10.2M | 7.4M | 6.8M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Cash and equivalents | $221.8K | $748.7K | $619.6K | - |
| Short-term investments | - | $2.26M | $2.30M | - |
| Receivables | - | $4.66M | $3.70M | - |
| Inventory | $360.1K | $560.0K | $933.3K | - |
| Current assets | $12.33M | $8.73M | $7.80M | - |
| Total assets | $12.84M | $9.42M | $8.67M | - |
| Current liabilities | $3.20M | $2.92M | $3.18M | - |
| Long-term debt | - | $1.50M | $1.12M | - |
| Total debt | $877.9K | $1.50M | $1.12M | - |
| Total liabilities | $3.26M | $4.43M | $4.41M | - |
| Shareholders' equity | $9.63M | $4.99M | $4.25M | $585.2K |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Operating cash flow | -$751.6K | $569.2K | -$394.3K | $1.73M |
| Capital expenditures | $35.5K | $69.9K | $52.7K | $114.6K |
| Free cash flow | -$787.1K | $499.3K | -$447.1K | $1.61M |
| Investing cash flow | $857.5K | -$2.45M | -$40.8K | -$132.1K |
| Financing cash flow | -$630.2K | $2.00M | $537.3K | -$1.16M |
| Depreciation and amortization | $86.5K | $75.8K | $64.2K | $74.0K |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Revenue growth, YoY | -33.9% | 21.7% | 32.9% | - |
| Net income growth, YoY | - | - | 33.2% | - |
| EPS growth, YoY | - | - | 23.3% | - |
| Gross margin | 10.3% | 11.9% | 21.3% | 21.8% |
| Operating margin | -17.8% | -11.2% | -11.7% | -14.3% |
| Net margin | -8.5% | -0.1% | 8.0% | 7.9% |
| Free cash flow margin | -5.9% | 2.5% | -2.7% | 12.8% |
| Return on equity | -11.8% | -0.5% | 31.3% | 170.6% |
| Return on assets | -8.8% | -0.3% | 15.3% | - |
| Current ratio | 3.86 | 2.99 | 2.46 | - |
| Debt to equity | 0.09 | 0.30 | 0.26 | - |
Source: XBRL data Cellyan Biotechnology Co. Ltd files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
HKPD peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| HKPD | $13.43M | -33.9% | -$1.14M | -8.5% | $3.8M |
| MCK | $418.79B | +8.2% | $4.70B | 1.1% | $122.31B |
| COR | $332.77B | +5.1% | $2.62B | 0.8% | $65.98B |
| CAH | $254.25B | +14.2% | $1.71B | 0.7% | $63.40B |
| HLF | $5.28B | +6.4% | $179.80M | 3.4% | $1.65B |
| NUS | $1.32B | -15.3% | -$234.21M | -17.7% | $208.3M |
| ZSTK | $40.03M | +27.3% | -$177.84M | -444.2% | $58.7M |
| ESYN | $389.7K | -68.5% | -$2.65M | -680.2% | $43.1M |
| COSM | $73.73M | +33.8% | -$24.39M | -33.1% | $27.6M |
HKPD FAQ
9 questionsWhat is HKPD revenue?
Cellyan Biotechnology Co. Ltd (HKPD) reported $13.43M of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 33.9% from the year before.Is HKPD profitable?
No. Cellyan Biotechnology Co. Ltd reported a net loss of $1.14M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does HKPD have?
Cellyan Biotechnology Co. Ltd reported $221.8K in cash and cash equivalents and $877.9K of debt on its most recent balance sheet in SEC filings.How fast is HKPD revenue growing?
Cellyan Biotechnology Co. Ltd's revenue changed -33.9% in fiscal 2026, to $13.43M.What is HKPD gross margin?
Cellyan Biotechnology Co. Ltd's gross profit was $1.39M on $13.43M of revenue for fiscal 2026 (ended Mar 31, 2026), a gross margin of 10.3%.What is HKPD free cash flow?
Cellyan Biotechnology Co. Ltd generated -$787.1K of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of -$751.6K less capital expenditures.What is HKPD earnings per share?
Diluted earnings per share were -$0.07 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did HKPD last report financial results?
The latest statements here come from Cellyan Biotechnology Co. Ltd's 20-F filed on Aug 7, 2026, covering the period ended Mar 31, 2026.Where does this HKPD financial data come from?
Quantisnow builds these statements from the structured XBRL data Cellyan Biotechnology Co. Ltd files with the SEC. It is provided for information only and is not investment advice.